Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

Biochemical Pharmacology

Volumn 59, Issue 8, 2000, Pages 927-935

  Vanderheyden, Patrick M L ^a   Fierens, Frederik L P ^a   De Backer, Jean Paul ^a   Vauquelin, Georges ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

AT1 antagonists; Candesartan; CHO cells; EXP3174; Inositol phosphate; Insurmountable; Irbesartan; Losartan; Surmountable

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL; DRUG MECHANISM; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; INOSITOL PHOSPHATES; RADIOLIGAND ASSAY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TRITIUM;

EID: 0033969912     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00403-7     Document Type: Article

References (33)

1. Vallotton M.B. The renin-angiotensin system. Trends Pharmacol Sci. 8:1987;69-74.
2. Robertson M.J. Angiotensin antagonists. Leff P. Receptor-Based Drug Design. 1998;207-229 Marcel Dekker, New York.
3. 1 receptor. J Biol Chem. 270:1995;1493-1496.
4. 1 receptors. Br J Pharmacol. 126:1999;1057-1065.
5. 1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol. 367:1999;413-422.
6. 1 receptor antagonists The role of tight antagonist binding . Eur J Pharmacol. 372:1999;199-206.
7. Gaddum J.H., Hameed K.A., Hathaway D.E., Stephens F.F. Quantitative studies on antagonists for 5-hydroxytryptamine. Q J Exp Physiol. 40:1955;49-74.
8. Mochizuki S., Sato T., Furata K., Hase K., Ohkura Y., Fukai C., Kosakai K., Wakabayashi S., Tomiyama A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol. 25:1995;22-29.
9. Liu Y.J., Shankley N.P., Welsh N.J., Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br J Pharmacol. 106:1992;233-241.
10. 1 receptor antagonist . Br J Pharmacol. 107:1992;1173-1180.
11. 1-receptor subtype . Br J Pharmacol. 110:1993;761-771.
12. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 265:1993;826-834.
13. Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol. 46:1993;311-318.
14. Pendleton R.G., Gessner G., Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal and aorta. J Pharmacol Exp Ther. 248:1989;637-643.
15. Hara M., Kiyama R., Nakajima S., Kawabata T., Kawakami M., Ohtani K., Itazaki K., Fujishita T., Fujimoto M. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol. 289:1995;267-273.
16. 1 receptor antagonist, UR-7280. Eur J Pharmacol. 318:1996;341-347.
17. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 110:1993;245-252.
18. Olins G.M., Chen S.T., McMahon E.G., Palomo M.A., Reitz D.B. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol Pharmacol. 47:1994;115-120.
19. Dickinson K.E., Cohen R.B., Skwish S., Delaney C.L., Serafino R.P., Poss M.A., Gu Z., Ryono D.E., Moreland S., Powell J.R. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses Comparison with losartan and EXP3174 . Br J Pharmacol. 113:1994;179-189.
20. 1 receptor antagonist. Br J Pharmacol. 114:1995;1117-1124.
21. 1 receptor. Eur J Pharmacol. 319:1997;137-146.
22. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[ [ 2′-(1H-tetrazol-5-yl)biphenyl-4-yl ] methyl ]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther. 266:1993;114-120.
23. Wong P.C., Price A.W., Chiu A.T., Duncia J.V., Carini D.J., Wexler R., Johnson A., Timmermans P.B. Nonpeptide angiotensin receptor antagonists. XI. Pharmacology of EXP3174 An active metabolite of DuP 753, an orally active antihypertensive agent . J Pharmacol Exp Ther. 255:1990;211-217.
24. Arunlakshana O., Schild H.O. Some quantitative uses of drugs antagonists. Br J Pharmacol. 14:1959;48-52.
25. Wienen W., Mauz A.B., Van Meel J.C., Entzeroth M. Different type of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol. 41:1992;1081-1088.
26. Inoue Y., Nakamura N., Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hyperten. 15:1997;703-714.
27. 1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. Biochem Biophys Res Commun. 209:1995;153-160.
28. Schambye H.T., Hjorth S.A., Bergsma D.J., Sathe G., Schwartz T.W. Differentiation between binding sites for angiotensin II and non-peptide antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci U S A. 91:1994;7046-7050.
29. Kostenis E., Mohr K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci. 17:1996;280-283.
30. Wong P.C., Timmermans P.B. Nonpeptide angiotensin II receptor antagonists Insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753 . J Pharmacol Exp Ther. 258:1991;49-57.
31. 2 receptor antagonists but allosteric modulators. Naunyn Schmiedebergs Arch Pharmacol. 335:1987;359-366.
32. 1 receptor antagonist. J Cardiovasc Pharmacol. 25:1995;354-360.
33. Limbird L.E. A short course on theory and methods. Limbird L.E. Cell Surface Receptors. 1996;61-122 Kluwer Academic Publishing, Boston.